HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties.

Abstract
The formation of a new vascular network by angiogenesis is a key driver in tumor growth and metastasis, making this an attractive therapeutic target. Different strategies are being developed to either prevent tumor angiogenesis or disrupt the tumor vasculature already in place. In this in vitro study, we investigated the antivascular properties of ENMD-1198, a new anticancer drug currently in clinical trials. ENMD-1198 is a new analogue of 2-methoxyestradiol, a microtubule-targeting agent that has shown promising results in the treatment of multiple myeloma and hormone-refractory prostate cancer. Using both bone marrow-derived and dermal microvascular endothelial cell lines, we analyzed the effect of ENMD-1198 on the different functions of endothelial cells involved in angiogenesis. In both cell lines, ENMD-1198 was more potent than 2-methoxyestradiol at inhibiting endothelial cell proliferation, motility, migration, and morphogenesis. In addition, ENMD-1198 induced a significant decrease in vascular endothelial growth factor receptor-2 protein expression in endothelial cells. Furthermore, videomicroscopy experiments showed that ENMD-1198 was able to completely disrupt preformed vascular structures within 2 hours. This vascular-disrupting activity was associated with extensive depolymerization of the microtubule network and accumulation of actin stress fibers and large focal adhesions in vascular endothelial cells. Collectively, our results show that this new compound displays potent antivascular properties, and this study provides important insights into the mechanism of action of this promising new anticancer drug.
AuthorsEddy Pasquier, Snega Sinnappan, Marcia A Munoz, Maria Kavallaris
JournalMolecular cancer therapeutics (Mol Cancer Ther) Vol. 9 Issue 5 Pg. 1408-18 (May 2010) ISSN: 1538-8514 [Electronic] United States
PMID20442304 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 2-methoxyoestra-1,3,5(10),16-tetraene-3-carboxamide
  • Angiogenesis Inhibitors
  • Estrenes
  • Tubulin Modulators
  • Estradiol
  • 2-Methoxyestradiol
Topics
  • 2-Methoxyestradiol
  • Angiogenesis Inhibitors (pharmacology, therapeutic use)
  • Blood Vessels (drug effects)
  • Cell Movement (drug effects)
  • Cell Proliferation (drug effects)
  • Cells, Cultured
  • Cytoskeleton (drug effects, metabolism, physiology)
  • Drug Evaluation, Preclinical
  • Endothelial Cells (drug effects, physiology)
  • Estradiol (analogs & derivatives, chemistry)
  • Estrenes (pharmacology, therapeutic use)
  • Humans
  • Male
  • Neovascularization, Pathologic (pathology, prevention & control)
  • Neovascularization, Physiologic (drug effects)
  • Tubulin Modulators (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: